Knee Osteoarthritis Market Set to Reach USD 26,000 Million by 2036

DelveInsight's "Knee Osteoarthritis - Market Insights, Epidemiology and Market Forecast - 2036" report delivers an in-depth understanding of knee osteoarthritis, historical and forecasted epidemiology, and market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

To know in detail about the knee osteoarthritis market outlook, treatment uptake, and competitive landscape, click here: https://www.delveinsight.com/report-store/knee-osteoarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Some of the Key Facts of the Knee Osteoarthritis Market Report
• The knee osteoarthritis market size in the leading markets (US, EU4, UK, and Japan) was found to be approximately USD 15,500 million in 2025, and is projected to reach approximately USD 26,000 million by 2036, growing at a CAGR of 5% during 2026-2036.
• The US accounted for the largest market size among the 7MM, at approximately USD 9,600 million in 2025, while among EU4, the UK and Germany hold the largest market shares, followed by France.
• Research suggests women are almost twice as likely to develop osteoarthritis as men, with the female population contributing to about 63% of knee osteoarthritis cases in the US.
• The US accounted for around 1,937,600 diagnosed prevalent cases of knee osteoarthritis in 2025, while Germany recorded nearly 6,972,862 diagnosed prevalent cases the same year - the highest among EU4 and the UK, followed by France, with Italy recording the lowest.
• Approximately 10% of adults in the UK have been clinically diagnosed with osteoarthritis, compared to about 11.5% in the US and a global prevalence of roughly 16%.
• In January 2026, Biosplice submitted an NDA to the FDA for lorecivivint (LOR), the first disease-modifying candidate for knee osteoarthritis, showing statistically and clinically significant improvements in pain, function, and medial joint space width versus placebo.
• Approved intra-articular therapies such as JOYCLU, TRILURON, and ZILRETTA currently anchor the market, offering localized and sustained pain control as effective non-surgical options.
• Emerging companies developing knee osteoarthritis therapies include Paradigm Biopharma (ZILOSUL), Amzell (AMZ001), and CellSeed (CLS2901C), with late-stage candidates expected to intensify competition through the latter half of the forecast period.

Key Knee Osteoarthritis Companies
• Ono Pharmaceutical, Fidia Farmaceutici, Pacira BioSciences, Paradigm Biopharma, Amzell, CellSeed, and others.

Key Knee Osteoarthritis Therapies
• JOYCLU, TRILURON, ZILRETTA, ZILOSUL, AMZ001, CLS2901C, and others.
• The knee osteoarthritis market is expected to grow due to the rising prevalence of the condition among an aging population and a growing shift toward minimally invasive, non-surgical treatment alternatives. The entry of disease-modifying and regenerative pipeline candidates is expected to significantly reshape the competitive landscape during the forecast period.

Knee Osteoarthritis Overview
Knee osteoarthritis, also known as degenerative joint disease, results from wear and tear and progressive loss of articular cartilage, and is most common in the elderly. It can be classified as primary (degeneration without an apparent underlying cause) or secondary (resulting from abnormal joint force, such as post-traumatic causes, or abnormal cartilage, such as in rheumatoid arthritis). Symptoms typically develop gradually as cartilage wears down over time. There is no single standard lab test for diagnosis; physicians typically rely on patient interviews, physical examinations, x-rays, MRIs, and lab tests to rule out other conditions.

Get a free sample for the Knee Osteoarthritis Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/knee-osteoarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Knee Osteoarthritis Market Segmentation
The knee osteoarthritis market report proffers detailed analysis for the study period 2022-2036 segmented into:
• By Region/Geography: North America (US); Europe (Germany, France, Italy, Spain, and the UK); Asia-Pacific (Japan)
• By Drugs/Therapies
• By Epidemiology Segmentation: Total, gender-specific, age-specific, and severity-specific prevalent cases

Download the report to understand which factors are driving knee osteoarthritis market trends: https://www.delveinsight.com/report-store/knee-osteoarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Knee Osteoarthritis Treatment Landscape
Current treatment options include NSAIDs, opioids, intra-articular corticosteroids, and intra-articular hyaluronic acid. Approved therapies include JOYCLU (Ono Pharmaceutical/Seikagaku Corporation), TRILURON (Fidia Farmaceutici), and ZILRETTA (Pacira BioSciences/Flexion Therapeutics). ZILRETTA delivers a corticosteroid via PLGA microspheres for sustained intra-articular release, minimizing systemic exposure while controlling inflammation and pain over several months. Emerging pipeline candidates such as ZILOSUL (pentosan polysulfate sodium, Paradigm Biopharma) are being investigated for their potential to reduce cartilage degradation and joint inflammation, pointing toward a shift in the market toward disease-modifying and regenerative approaches.

Discover more about therapies set to grab major knee osteoarthritis market share: https://www.delveinsight.com/report-store/knee-osteoarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Knee Osteoarthritis Market Strengths
• A well-established base of approved intra-articular therapies (JOYCLU, TRILURON, ZILRETTA) provides localized, sustained pain relief with reduced systemic exposure.
• Growing patient and physician preference for non-surgical alternatives, such as hyaluronic acid injections and platelet-rich plasma, over traditional oral medications.
• An active late-stage pipeline - including lorecivivint, ZILOSUL, AMZ001, and CLS2901C - is advancing disease-modifying and regenerative treatment options.

Knee Osteoarthritis Market Opportunities
• The rising global aging population and increasing joint degeneration are driving sustained, long-term demand for both approved and emerging knee osteoarthritis therapies.
• Regulatory momentum including RMAT designation for GNSC-001 and an NDA submission for lorecivivint is opening pathways for faster market entry of next-generation, disease-modifying treatments.

Scope of the Knee Osteoarthritis Market Report
• Study Period: 2022-2036
• Historical Year: 2022-2025 | Base Year: 2026 | Forecast Period: 2026-2036
• Coverage: The US; Germany, France, Italy, Spain, and the UK; Japan
• Key Companies: Ono Pharmaceutical, Fidia Farmaceutici, Pacira BioSciences, Paradigm Biopharma, Amzell, CellSeed, and others
• Key Therapies: JOYCLU, TRILURON, ZILRETTA, ZILOSUL, AMZ001, CLS2901C, and others
• Market CAGR (Forecast Period): 5% (2026-2036)
• Analysis Includes: KOL views, SWOT analysis, reimbursement, conjoint analysis, unmet needs, market drivers and barriers, epidemiology patient burden

To know more about knee osteoarthritis companies working in the market, visit: https://www.delveinsight.com/report-store/knee-osteoarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Table of Contents
1. Knee Osteoarthritis Market Report Introduction
2. Executive Summary for Knee Osteoarthritis
3. SWOT Analysis of Knee Osteoarthritis
4. Knee Osteoarthritis Market Overview at a Glance
5. Knee Osteoarthritis Disease Background and Overview
6. Knee Osteoarthritis Market Segmentation and Analysis
7. Regional Analysis of the Knee Osteoarthritis Market
8. Country-Specific Knee Osteoarthritis Market Analysis
9. Competitive Landscape and Key Company Profiles
10. Knee Osteoarthritis Unmet Needs
11. Knee Osteoarthritis Emerging Therapies and Pipeline
12. Knee Osteoarthritis Market Outlook
13. Knee Osteoarthritis Market Access and Reimbursement
14. Knee Osteoarthritis Market Drivers
15. Knee Osteoarthritis Market Barriers
16. Knee Osteoarthritis Recent Developments
17. Knee Osteoarthritis Appendix
18. Knee Osteoarthritis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432, Las Vegas, Nevada 89107, United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma and diagnostics companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.